Persistence of cardiovascular risk after rofecoxib discontinuation

Arch Intern Med. 2010 Dec 13;170(22):2035-6. doi: 10.1001/archinternmed.2010.461.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Cardiovascular Diseases / chemically induced*
  • Cyclooxygenase 2 Inhibitors / administration & dosage
  • Cyclooxygenase 2 Inhibitors / adverse effects*
  • Drug Administration Schedule
  • Female
  • Humans
  • Incidence
  • Kaplan-Meier Estimate
  • Lactones / administration & dosage
  • Lactones / adverse effects*
  • Male
  • Middle Aged
  • Odds Ratio
  • Proportional Hazards Models
  • Randomized Controlled Trials as Topic
  • Retrospective Studies
  • Risk Factors
  • Sulfones / administration & dosage
  • Sulfones / adverse effects*
  • Time Factors

Substances

  • Cyclooxygenase 2 Inhibitors
  • Lactones
  • Sulfones
  • rofecoxib